NextCure
Biotechnology · 135 employees
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. We view the immune system holistically and, rather than target one specific immune cell type, we focus on understanding biological pathways, the interactions of cells and the role
Funding history
- Funding Round — $21.5M — Dec 2025
- Series private placement — $10.0M — Nov 2025
- Funding Round — $93.4M — Nov 2018
- Funding Round — $15.0M — Jan 2016
Recent signals
- Dec 10, 2025: Raised $21.5M
- Nov 17, 2025: Raised $10.0M in Series private placement
- Nov 12, 2025: SEC 8-K (1.01): On November 12, 2025, NextCure, Inc. entered into a securities purchase agreement with institutional and accredited investors for a private placement. The agreement includes the sale of 708,428 shares of common stock at a price of $8.52 per share and pre-funded warrants for the purchase of up to 1,815,049 shares at a price of $8.519 per warrant. This private offering aims to raise capital for the company, and has implications for NextCure's financing strategy in the competitive biotech market.
- Jun 16, 2025: NextCure and Simcere Zaiming Form Strategic Partnership for SIM0505, an Antibody-Drug Conjugate Targeting CDH6.
- Nov 19, 2018: Raised $93.4M
- Jan 11, 2016: Raised $15.0M
See plans & pricing → Track NextCure’s funding, hiring, and signals — with verified contacts — on Fundz.